NVIV Key Stats
- InVivo Therapeutics Appoints Lou Vaickus, MD as Interim Chief Medical Officer Business Wire Oct 11
- New CEO Should Right InVivo's Ship Seeking Alpha Oct 9
- INVIVO THERAPEUTICS HOLDINGS CORP. Financials Oct 1
- InVivo Therapeutics to Present at 2013 Aegis Healthcare Conference Business Wire Sep 23
- INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Sep 17
- InVivo Therapeutics Appoints Gregory D. Perry as Interim CFO Business Wire Sep 17
- INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Sep 10
- InVivo Therapeutics (NVIV) Acting CFO Resigns Street Insider Sep 9
- InVivo Therapeutics Announces Personnel Changes Business Wire Sep 9
- InVivo Therapeutics to Present at 15th Annual Rodman and Renshaw Healthcare Conference Business Wire Sep 5
NVIV Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). InVivo Therapeutics is up 0.00% over the last year vs S&P 500 Total Return up 30.02%, RTI Surgical down 30.80%, and Cutera down 9.93%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for NVIV
Pro Strategies Featuring NVIV
Did InVivo Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
InVivo Therapeutics Holdings Corp. develops and commercializes technologies for the treatment of spinal cord injuries.